Viking Therapeutics (VKTX) Competitors $28.61 -0.26 (-0.90%) Closing price 04:00 PM EasternExtended Trading$28.69 +0.08 (+0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MRNA, ASND, VTRS, QGEN, ROIV, RVMD, LNTH, BBIO, TGTX, and LEGNShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Viking Therapeutics vs. Moderna Ascendis Pharma A/S Viatris Qiagen Roivant Sciences Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Legend Biotech Moderna (NASDAQ:MRNA) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations. Do insiders and institutionals hold more shares of MRNA or VKTX? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, MRNA or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Moderna. Viking Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.20B3.27-$3.56B-$9.28-2.91Viking TherapeuticsN/AN/A-$109.96M-$1.15-24.89 Do analysts rate MRNA or VKTX? Moderna currently has a consensus target price of $58.70, suggesting a potential upside of 117.17%. Viking Therapeutics has a consensus target price of $87.15, suggesting a potential upside of 204.52%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is MRNA or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Viking Therapeutics' return on equity of -11.93% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-110.04% -28.74% -21.83% Viking Therapeutics N/A -11.93%-11.57% Does the media favor MRNA or VKTX? In the previous week, Viking Therapeutics had 16 more articles in the media than Moderna. MarketBeat recorded 57 mentions for Viking Therapeutics and 41 mentions for Moderna. Moderna's average media sentiment score of 0.78 beat Viking Therapeutics' score of 0.15 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 17 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 11 Negative mention(s) 2 Very Negative mention(s) Positive Viking Therapeutics 15 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community believe in MRNA or VKTX? Viking Therapeutics received 420 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 53.62% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21553.62% Underperform Votes18646.38% Viking TherapeuticsOutperform Votes63580.08% Underperform Votes15819.92% Which has more risk and volatility, MRNA or VKTX? Moderna has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. SummaryViking Therapeutics beats Moderna on 13 of the 18 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.21B$6.71B$5.49B$7.95BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-28.627.3522.6218.58Price / SalesN/A241.98397.85103.49Price / CashN/A65.8538.1834.62Price / Book8.226.496.744.25Net Income-$109.96M$143.41M$3.22B$248.18M7 Day Performance11.54%2.24%1.59%1.36%1 Month Performance19.70%7.16%4.09%3.85%1 Year Performance-62.55%-2.45%15.98%5.37% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics4.4904 of 5 stars$28.61-0.9%$87.15+204.6%-63.7%$3.21BN/A-28.6120Analyst ForecastOptions VolumeAnalyst RevisionMRNAModerna4.431 of 5 stars$27.35+0.5%$58.70+114.6%-74.1%$10.57B$3.20B-2.953,900Earnings ReportNews CoverageASNDAscendis Pharma A/S2.3101 of 5 stars$164.42+0.2%$204.67+24.5%+23.1%$10.08B$363.64M-23.28640Earnings ReportNews CoveragePositive NewsVTRSViatris1.832 of 5 stars$8.24+1.3%$10.50+27.5%-27.2%$9.83B$14.74B-11.1337,000Upcoming EarningsQGENQiagen3.6875 of 5 stars$42.21+0.3%$47.83+13.3%+4.0%$9.39B$1.98B117.566,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2017 of 5 stars$11.15+1.2%$17.50+57.0%+6.6%$7.95B$122.59M-74.30860Positive NewsRVMDRevolution Medicines3.7619 of 5 stars$41.39+6.8%$66.67+61.1%+8.3%$7.70B$742,000.00-11.53250Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9658 of 5 stars$102.54+0.8%$129.43+26.2%+56.8%$7.02B$1.53B17.06700Upcoming EarningsNews CoveragePositive NewsBBIOBridgeBio Pharma4.5542 of 5 stars$35.31-2.8%$53.00+50.1%+49.7%$6.70B$221.90M-12.39400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageTGTXTG Therapeutics3.3201 of 5 stars$41.48+0.4%$40.67-2.0%+233.2%$6.59B$329.00M-414.72290Upcoming EarningsNews CoveragePositive NewsLEGNLegend Biotech2.6389 of 5 stars$34.35+0.2%$78.82+129.5%-20.1%$6.31B$627.24M-36.161,070Positive News Related Companies and Tools Related Companies Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Revolution Medicines Competitors Lantheus Competitors BridgeBio Pharma Competitors TG Therapeutics Competitors Legend Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behin...Stansberry Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
